1459 GMT - AstraZeneca's trial results for breast cancer pill Camizestrant are a material positive surprise and clear the first of its major late-stage catalysts for this year, Barclays analysts say in a note. The British pharma giant's results showed the drug candidate helped patients live for longer without their disease worsening. AstraZeneca guides for a more than $5 billion peak sales potential, whereas Barclays anticipates $3.6 billion. The company indicated it would release most key results in 2H, leading to the analysts expecting publication in the middle of the summer. Shares are up 0.1% at 119.46 pounds.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 26, 2025 09:59 ET (14:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.